Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

Novavax Inc. shares rose after US regulators asked for more data on its Covid vaccine, signaling the shot may be on a path to ...

Novavax has shared positive preliminary results from a real-world study of its JN.1-adapted COVID-19 vaccine. The SHIELD-Utah ...

The current US domestic news highlights involve President Trump's stance on Federal Reserve Chair Jerome Powell, cybercrime ...

Investing.com -- Novavax (NASDAQ: NVAX) shares surged 13% following the biotechnology company’s optimism about its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

Yesterday, Novavax presented early data from a real-world study suggesting that its 2024-25 protein-based COVID-19 vaccine ...

Novavax (NVAX) closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...

Complex Pandemic Accord negotiations have been under way since 2021, with 13 formal meetings and numerous informal sessions.